Key statistics dashboard for Genenta Science S.p.A. (GNTA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter.
Stock Data
| Price | $0.74 |
| Market Cap | $14M |
| Beta | 0.71 |
| Exchange | NASDAQ |
| Country | IT |
Valuation Multiples
| P/E Ratio | -2.18 |
| Price / Book | 0.70 |
| P/S | 0.00 |
| P/FCF | -1.78 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 14.16 |
| Quick Ratio | 14.16 |
| Cash Ratio | 2.61 |
| Debt / Equity | 0.35 |
| Debt / Assets | 23.84% |
| Interest Coverage | -17.01 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.03 |
| Cash per share | 1.33 |
| FCF per share | -0.36 |
| Tangible Book Value per share | 1.03 |
| Dividend per share | 0.00 |
Related companies: BRNS · CVM · INMB · IPSC · JUNS · MDCX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of GNTA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks